Loading stock data…
$1.48+0.03 (+2.07%)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OS Therapies Incorporated in the Healthcare sector is trading at $1.48 with a market capitalization of $81M. Wall Street consensus targets $8.50 (4 analysts), implying a +474.3% move over the next 12 months. The stock is currently 34% below its 52-week high of $2.25, remaining 6.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.58M↑ | -$10.17M↑ | -$11.99M↓ | -$6.88M↓ | -$4.84M |
| Net Income | -$8.63M↑ | -$10.40M↑ | -$13.46M↓ | -$6.88M↓ | -$4.54M |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-H...